Centocor, Inc. has received approval from the FDA for Remicade for reducing signs and symptoms and inducing clinical remission in pediatric patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response to conventional therapy. This approval establishes Remicade as the first biologic therapy approved for the treatment of pediatric Crohn’s disease, a debilitating condition that causes inflammation of the gastrointestinal tract, typically resulting...